

# ÆTERNA ZENTARIS' PIPELINE ENCOMPASSES COMPOUNDS AT ALL STAGES OF DEVELOPMENT, FROM DRUG DISCOVERY THROUGH MARKETED PRODUCTS

THE TWO HIGHEST PRIORITY CLINICAL PROGRAMS ARE OUR LEAD VALUE DRIVER, CETRORELIX, FOR BENIGN PROSTATIC HYPERPLASIA AND OUR LEAD ONCOLOGY PROGRAM, AEZS-108, FOR ENDOMETRIAL AND OVARIAN CANCER.

**Preclinical**

**AEZS-115**  
(endometriosis & urology)

**AEZS-120**  
(oncology vaccine)

**Erk/PI3K  
INHIBITORS**  
(oncology)

**GHRELIN  
RECEPTOR  
LIGANDS**  
(endocrinology)

**AEZS-127**  
(oncology)

**Partners:** **AEZS-127:**  
Keryx

Discovery Unit:  
120,000 compound library

Status as of December 31, 2007

## Phase 1

### **AEZS-112**

(oncology)

### **AEZS-130**

(endocrinology)

## Phase 2

### **AEZS-108**

(endometrial and ovarian cancer)

Initiated in the second half of 2007 with a study period of approximately 24 months

## Phase 3

### **CETRORELIX**

(benign prostatic hyperplasia)

Initiated in the first half of 2007 with results expected in the second half of 2009

## Commercial

### **CETROTIDE®**

(*in vitro* fertilization)

### **IMPAVIDO®**

(leishmaniasis, better known as black fever)

### **CETRORELIX**

(endometriosis)  
(BPH in Japan)

### **OZARELIX**

(BPH, prostate cancer)

### **PERIFOSINE**

(multiple cancers)

### **AEZS-130:**

Ardana

### **CETRORELIX**

Shionogi in Japan

### **OZARELIX**

Spectrum in North America and India, Nippon Kayaku in Japan

### **PERIFOSINE**

Keryx in North America

### **CETROTIDE®**

Merck Serono,  
World ex-Japan  
Shionogi & Nippon Kayaku  
in Japan